These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 3025983)

  • 21. Effects of long-term treatment with enalapril or hydralazine on the renin-angiotensin-aldosterone system and fluid balance in dogs with naturally acquired mitral valve regurgitation.
    Häggström J; Hansson K; Karlberg BE; Kvart C; Madej A; Olsson K
    Am J Vet Res; 1996 Nov; 57(11):1645-52. PubMed ID: 8915446
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Conceptual and therapeutic approaches to inhibition of the renin-angiotensin system in chronic heart failure.
    Cody RJ
    J Cardiovasc Pharmacol; 1986; 8 Suppl 1():S58-65. PubMed ID: 2422494
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Age and the pharmacodynamics of angiotensin converting enzyme inhibitors enalapril and enalaprilat.
    Ajayi AA; Hockings N; Reid JL
    Br J Clin Pharmacol; 1986 Apr; 21(4):349-57. PubMed ID: 3011047
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The renin-angiotensin system in refractory heart failure: clinical, hemodynamic and hormonal effects of captopril and enalapril.
    Turini GA; Waeber B; Brunner HR
    Eur Heart J; 1983 Jan; 4 Suppl A():189-97. PubMed ID: 6301835
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of dietary sodium on angiotensin-converting enzyme (ACE) inhibition and the acute hypotensive effect of enalapril (MK-421) in essential hypertension.
    Jackson B; Cubela R; Johnston CI
    J Hypertens; 1984 Aug; 2(4):371-7. PubMed ID: 6099390
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical pharmacology of enalapril.
    Abrams WB; Davies RO; Gomez HJ
    J Hypertens Suppl; 1984 Dec; 2(2):S31-6. PubMed ID: 6100874
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical pharmacokinetics of the angiotensin converting enzyme inhibitors. A review.
    Kubo SH; Cody RJ
    Clin Pharmacokinet; 1985; 10(5):377-91. PubMed ID: 2994938
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Suppression of plasma aldosterone by chronic ACTH administration is offset by converting enzyme inhibitor.
    Fukuda N; Honda M; Watanabe M; Minato M; Hatano M
    Endocrinol Jpn; 1987 Oct; 34(5):665-73. PubMed ID: 2830100
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of the oral converting enzyme inhibitor SQ 14225 in experimental high output failure.
    Williams GM; Davis JO; Freeman RH; DeForrest JM; Seymour AA; Rowe BP
    Am J Physiol; 1979 Jun; 236(6):F541-5. PubMed ID: 220888
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Haemodynamic, hormonal, and electrolyte effects of enalapril in heart failure.
    Fitzpatrick D; Nicholls MG; Ikram H; Espiner EA
    Br Heart J; 1983 Aug; 50(2):163-9. PubMed ID: 6309203
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Systemic and coronary haemodynamics and pharmacodynamics of enalapril and enalaprilat in congestive heart failure.
    Chatterjee K; De Marco T
    Drugs; 1990; 39 Suppl 4():29-40; discussion 41-2. PubMed ID: 2162294
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Elevated plasma aldosterone levels despite complete inhibition of the vascular angiotensin-converting enzyme in chronic heart failure.
    Jorde UP; Vittorio T; Katz SD; Colombo PC; Latif F; Le Jemtel TH
    Circulation; 2002 Aug; 106(9):1055-7. PubMed ID: 12196328
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acute hemodynamic and hormonal effects of MK-521 in congestive heart failure.
    Dickstein K; Aarsland T; Woie L; Kremer D; Abrahamsen AM
    Scand J Urol Nephrol Suppl; 1984; 79():125-7. PubMed ID: 6089311
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Endogenous bradykinin suppresses myocardial fibrosis through the cardiac-generated endothelin system under chronic angiotensin-converting enzyme inhibition in heart failure.
    Fujii M; Wada A; Ohnishi M; Tsutamoto T; Matsumoto T; Yamamoto T; Takayama T; Dohke T; Isono T; Eguchi Y; Horie M
    J Cardiovasc Pharmacol; 2004 Nov; 44 Suppl 1():S346-9. PubMed ID: 15838317
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of the effect of renin inhibition and angiotensin-converting enzyme inhibition in ovine heart failure.
    Fitzpatrick MA; Rademaker MT; Charles CJ; Yandle TG; Espiner EA; Ikram H; Nussberger J
    J Cardiovasc Pharmacol; 1992 Feb; 19(2):169-75. PubMed ID: 1376784
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neurohormonal reactivation in heart failure patients on chronic ACE inhibitor therapy: a longitudinal study.
    Lee AF; MacFadyen RJ; Struthers AD
    Eur J Heart Fail; 1999 Dec; 1(4):401-6. PubMed ID: 10937954
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of a new angiotensin converting enzyme inhibitor, enalapril, in acute and chronic left ventricular failure in dogs.
    Leddy CL; Wilen M; Franciosa JA
    J Clin Pharmacol; 1983; 23(5-6):189-98. PubMed ID: 6308067
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increase in vasoactive intestinal polypeptides (VIP) by the angiotensin converting enzyme (ACE) inhibitor lisinopril in congestive heart failure. Relation to haemodynamic and hormonal changes.
    Woie L; Dickstein K; Kaada B
    Gen Pharmacol; 1987; 18(6):577-87. PubMed ID: 2822521
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of acute angiotensin converting enzyme inhibition on renal blood flow in patients with stable congestive heart failure.
    Le Jemtel TH; Maskin CS; Chadwick B
    Am J Med Sci; 1986 Sep; 292(3):123-7. PubMed ID: 3019136
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The changes of PRA, ATII, ald, ET and ANP in patients with left ventricular diastolic heart failure and intervention with enalapril].
    Zhuang H; Yu G; Li J; He J
    Hunan Yi Ke Da Xue Xue Bao; 1997; 22(4):323-6. PubMed ID: 9868087
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.